Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

References

• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52–iv61.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(Suppl 1):62–65.
   PubMedGoogle Scholar
• Cowan AJ, Allen C, Barac A, et al. Global Burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Kumar S. Evolving paradigms in the management of multiple myeloma: novel agents and targeted therapies. Rare Cancers Ther. 2015;3:47–68.
   PubMedGoogle Scholar
• Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol. 2012;49(Suppl 1):S16–S32.
   PubMedGoogle Scholar
• Moreau P. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol. 2012;49(Suppl 1):S33–S46.
   PubMed Web of Science ®Google Scholar
• Botta C, Ciliberto D, Rossi M, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Adv. 2017;1(7):455–466.
   PubMed Web of Science ®Google Scholar
• Dhakal B, Narra RK, Giri S, et al. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: a Bayesian network meta-analysis of phase 3 randomized controlled trials. Cancer. 2020;126(12):2791–2801.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kaufman JL, White D, et al. A comparison of the efficacy of immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a network meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18(3):163–173 e166.
   PubMed Web of Science ®Google Scholar
• Maiese EM, Ainsworth C, Le Moine JG, et al. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018;40(3):480–494 e423.
   PubMed Web of Science ®Google Scholar
• van Beurden-Tan CHY, Franken MG, Blommestein HM, et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol. 2017;35(12):1312–1319.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Dias S, et al. NICE DSU technical support document 2: a generalised linear modeling framework for pairwise and network meta-analysis of randomised controlled trials.
   Google Scholar
• Weisel K, Spencer A, Lentzsch S, et al. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol. 2020;13(1):115.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197.
   PubMed Web of Science ®Google Scholar
• Minarik J, Pika T, Radocha J, et al. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021;21(1):73.
   PubMed Web of Science ®Google Scholar
• Cameron C, Fireman B, Hutton B, et al. Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev. 2015;4:147.
   PubMed Web of Science ®Google Scholar
• Cope S, Toor K, Popoff E, et al. Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma. Value Health. 2020;23(4):441–450.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Suman VJ, McCarthy PL. Should overall survival remain an endpoint for multiple myeloma trials? Curr Hematol Malig Rep. 2019;14(1):31–38.
   PubMed Web of Science ®Google Scholar
• Kogan AJ, Haren M. Translating cancer trial endpoints into the language of managed care. Biotechnol Healthc. 2008;5(1):22–35.
   PubMedGoogle Scholar
• Saad ED, Buyse M. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol. 2016;27(3):373–378.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients With relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39(22):2430–2442.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Lonial S. What The princess bride teaches Us about outcomes in multiple myeloma. J Clin Oncol. 2021;39(22):2423–2425.
   PubMed Web of Science ®Google Scholar
• Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018;93(8):985–993.
   Web of Science ®Google Scholar
• Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116(16):3807–3814.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
   PubMed Web of Science ®Google Scholar
• Latimer NR. 2013. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. NICE Decision Support Unit. Available at: https://www.ncbi.nlm.nih.gov/books/NBK395885/pdf/Bookshelf_NBK395885.pdf.
   Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar